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Objectives This study tested the hypothesis that response to antiarrhythmic drugs (AADs) is modulated by 3 common loci
associated with atrial fibrillation (AF).
Background Recent genome-wide association studies have identified 3 loci, on chromosomes 4q25 (near PITX2), 16q22 (in
ZFHX3), and 1q21 (in KCNN3), that associate with either typical or lone AF. These findings indicate that variable
mechanisms contribute to AF susceptibility, and suggest that response to therapy may be genotype dependent.
Methods We studied 478 and 198 Caucasian patients in the discovery cohort and validation cohort, respectively, who
were prospectively enrolled in the Vanderbilt AF registry. Response was defined prospectively as successful
rhythm control if the patient remained on the same AAD therapy for a minimum of 6 months with 75% reduc-
tion in symptomatic AF burden. We also evaluated AF recurrence by 12-lead electrocardiogram (ECG) at 3, 6,
and 12 months. Symptomatic patients were also given a 24- to 48-h Holter monitor or 30-day event recorder
when AF recurrence was not captured by 12-lead ECG.
Results In the discovery cohort, 399 (83%) patients were successfully rhythm controlled. Multiple clinical variables (in-
cluding age, hypertension, lone AF) failed to significantly predict response to AADs; however, single nucleotide
polymorphism (SNP) rs10033464 at 4q25 was an independent predictor of successful rhythm control in pa-
tients with typical AF carrying the ancestral allele (wild type) versus carriers of variant allele (odds ratio [OR]:
4.7, 95% confidence interval [CI]: 1.83 to 12, p  0.0013. In the validation cohort, 143 (72%) patients met the
criteria for successful rhythm control, and rs10033464 was again an independent predictor of successful rhythm
control, OR: 1.5, 95% CI: 1.02 to 3.06, p  0.04. This SNP (rs10033464) was an independent predictor of AF
recurrence in the discovery (39% AF recurrence) and validation (38% AF recurrence) cohorts; OR: 3.27, 95% CI:
1.7 to 6, p  0.001 and OR: 4.3, 95% CI: 1.98 to 9.4, p  0.001, respectively.
Conclusions These results suggest that a common SNP on chromosome 4q25 associated with AF modulates response to
AAD therapy and points to a potential role for stratification of therapeutic approaches by genotype. (J Am Coll
Cardiol 2012;60:539–45) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.070Atrial fibrillation (AF) is the most common sustained
arrhythmia in clinical practice, representing a growing
epidemic with significant health consequences and affecting
more than 2 million adults in the United States (1). The
mean age of individuals with AF is 75 years; disease
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accepted January 17, 2012.prevalence increases with age (2.3% age40 years; 5.9% age
65 years) and with the presence of structural heart disease
such as ischemic, hypertensive, myocardial, or valvular
disease. Lone AF typically occurs in young and middle-age
adults (mean age at diagnosis 44 years) (2). Although
novel risk factors for this arrhythmia have recently been
described (3–5), the etiology of an individual’s condition
often remains unknown (6).
See page 546
A Mendelian pattern of inheritance has most often been
reported in AF kindreds, especially in probands with lone
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ing cardiac ion channels, gap
junction proteins, atrial natriuretic
peptide (ANP), and nucleoporins
(NUP155) have been reported in
isolated cases and small kindreds
(4,7–12). Recent genome-wide as-
sociation studies have identified 3
loci on chromosomes 4q25 (near
PITX2) (13), 16q22 (in ZFHX3)
(14,15), and 1q21 (in KCNN3)
(16), which associate with either
typical or lone AF. These find-
ings indicate that variable mechanisms contribute to AF
susceptibility, and suggest therefore that response to therapy
may also be genotype dependent. Within locus 4q25, 2
noncoding single nucleotide polymorphisms (SNPs)
(rs2200733 and rs10033464) were independently associated
with AF, and these findings were replicated in 2 populations
of European descent and 1 of Asian descent (13). Recently,
this association was replicated in a study of 4 large popula-
tions with ambulatory AF (17). This association has also
been reported for post-cardiac surgery AF, a setting
thought to be related to inflammation (18) and has
recently been reported to predict the likelihood of suc-
cessful AF ablation (19).
Understanding the molecular mechanisms of AF sup-
ports the idea that variability in drug therapy response is
modulated by various underlying disease mechanisms and
that drug response is as heterogeneous as the arrhythmia
itself. Antiarrhythmic agents remain the cornerstone of
treatment for patients with symptomatic AF despite the
high recurrence rate: 30% to 50% over 1 year. We tested the
hypothesis that response to antiarrhythmic drug (AAD)
therapy may also be genotype dependent by determining the
relationship between response to conventional AADs and
common SNPs that predict AF: rs2200733 and rs10033464
at 4q25, rs7193343 in ZFHX3, and rs13376333 in KCNN3.
Methods
Study population. The study was performed on prospec-
tively enrolled patients in the Vanderbilt AF registry.
Inclusion criteria included age 18 years and documented
history of AF with concurrent use of at least 1 conventional
AAD. At the time of enrollment, a detailed medical and
drug history was obtained along with a symptom question-
naire (20). The symptom questionnaire is a modification of
the validated University of Toronto AF severity scale (21)
and is repeated at 3, 6, and 12 months follow-up along with
12-lead electrocardiograms (ECGs) after starting an AAD.
In addition, any patient who experienced symptoms consis-
tent with AF not captured by 12-lead ECG was provided
with either a 24- to 48-h Holter monitor or 30-day event
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
CHF  congestive heart
failure
CI  confidence interval
ECG  electrocardiogram
OR  odds ratio
SNP  single nucleotide
polymorphismrecorder. Written informed consent was obtained from allpatients under a protocol approved by the Vanderbilt
University Institutional Review Board.
Definitions. Arterial hypertension was defined by a history
of hypertension and/or the presence of antihypertensive
therapy. Criteria for coronary artery disease included a
history of myocardial infarction or typical angina, previous
bypass surgery or angioplasty, and drug treatment. Conges-
tive heart failure (CHF) was defined by a history of CHF
and/or drug treatment for heart failure. Left atrial and left
ventricular measurements from the M-mode echocardio-
grams were made at the time enrollment if a recent echo
(3 months) was not available in the medical records. Echo-
cardiograms were read by an experienced physician blinded to
the genotype status of the patient. The echocardiograms were
evaluated according to the recommendations of the American
Society of Echocardiography. Lone AF was defined as AF
occurring in patients65 years of age without hypertension or
overt structural heart disease by clinical examination, ECG,
and echocardiography. AF recurrence was defined as presence
of documented AF on 12-lead ECG, Holter monitoring, or
pacemaker interrogations.
Response to AAD therapy. This was defined prospectively
as successful rhythm control if the patient remained on the
same AAD therapy for a minimum of 6 months with75%
reduction in symptomatic AF burden (the composite score
for frequency, duration, and severity of symptoms) on AAD
therapy (20). Nonresponse was defined as 75% reduction
in symptomatic AF burden score necessitating a change
to another AAD or to nonpharmacological therapy such
as atrioventricular node ablation and pacemaker implan-
tation. We also evaluated AF recurrence by 12-lead ECG
at 3-, 6-, and 12-month follow-up, Holter monitoring,
30-day event recorder, and, in some patients (2%), from
pacemaker interrogations (pacemakers inserted for sick
sinus syndrome).
Genotyping. Genomic DNA was isolated from whole
blood by a commercial kit (Purgene, Gentra Systems,
Minneapolis, Minnesota). Genotyping of the 2 4q25 SNPs
(rs2200733, rs10033464) was performed using real-time
polymerase chain reaction (PCR), iPlex single-base primer
extension, and matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry in a 384-well format (Seque-
nom, San Diego, California) as previously described (17).
Genotyping at the 16q22 (rs7193343 inZFHX3) and the 1q21
SNPs (rs13376333 in KCNN3) was performed using TaqMan
assays (Applied Biosystems, Foster City, California), as previ-
ously described (14,16), by laboratory personnel who had no
knowledge of the response to rhythm control therapy.
Statistical analysis. Data are expressed as mean  SD.
The Mann-Whitney U test was performed on continuous
variables and chi-square test on discrete variables. Logistic
regression analysis was done to determine odds ratio (OR)
and adjusted for type of AF (paroxysmal or persistent) and
sex using dominant and additive models. Due to expected
low numbers of homozygous variants, it was defined a priori
to include homozygous variants of all SNPs with their
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to test the association between AF recurrence within 12
months, as well as genetic polymorphism. Final dominant
model for AF recurrence was adjusted for age, sex, AF type,
history of hypertension, coronary artery disease, heart fail-
ure, diabetes, use of AADs, left ventricular ejection fraction,
and left atrial size in the discovery cohort and age, sex, AF
type, hypertension, and use of AADs in the validation
cohort.
In the dominant model, an identical effect is expected in
heterozygous and homozygous variant carriers, whereas in
the additive model, heterozygous variant carriers have an
intermediate effect in relation to the homozygotes. We used
Bonferroni correction to correct for multiple testing with
even distribution of significance (alpha) among the 4 tested
SNPs in the discovery cohort, with a 2-sided p value
0.0125 considered statistically significant. For validation
cohort (only 1 SNP tested), a 2-sided p value 0.05 was
considered statistically significant. All genetic analyses were
performed with PLINK.
Results
Our study population consisted of 478 and 198 Caucasian
patients enrolled in the discovery and validation cohorts,
respectively.
Clinical characteristics. The clinical characteristics of the
study cohorts are summarized in Table 1. The discovery
cohort consisted of 325 (68%) men, 152 (32%) women, age
63  13 years, 148 (31%) with lone AF, and hypertension
was the most common underlying comorbidity in 207 (43%)
patients. The validation cohort followed a similar trend: 129
(65%) men, 69 (35%) women, age 63  14 years, 53 (27%)
with lone AF, and hypertension was found in 100 (50%)
patients. Both study cohorts were similar with respect to
baseline demographics except for larger left atrial size (46 
8.6 mm) in the discovery cohort versus the validation cohort
(44  9 mm), p  0.005, and a marginal difference in left
Clinical Characteristics of the Study CohortTable 1 Clinical Characteristics of the Stud
Discovery (n  478)
AF type % Typical 69 Lone 31
Age, yrs 67 10 53 13
Age at onset, yrs 54 13 39 14
Male 217 (66) 108 (73
Comorbidities
Hypertension 207 (43) 0 (0)
Coronary artery disease 102 (21) 0 (0)
Congestive heart failure 66 (14) 0 (0)
Diabetes mellitus 65 (14) 0 (0)
Echocardiographic variables
Left atrial size, mm 46 8.6 42 10.
LVEF, % 52 14 56 9.0Values are n (%) and mean  SD. *Comparison between typical AF; †compa
AF  atrial fibrillation; LVEF  left ventricular ejection fraction.ventricular ejection fraction; 52  14% in the discovery
cohort versus 53  11% in the validation cohort, p  0.05
in patients with typical AF.
Genotyping. The frequencies of the common AF variants
between responders and nonresponders did not deviate
significantly from Hardy-Weinberg equilibrium. Table 2
shows the genotype frequencies of the tested SNPs in both
study cohorts.
Response to AAD therapy. In the discovery cohort, 399
(83.5%) patients met the criteria of successful rhythm
control. Response to therapy (successful rhythm control)
was significantly associated with rs10033464 in patients
with typical AF; allelic chi-square  0.0026, genotypic
hi-square  0.0008. There was marginal genotypic asso-
iation of the same SNP in the cumulative discovery cohort
typical and lone AF); chi-square  0.03.
Multiple clinical variables (including age, hypertension,
one AF) failed to significantly predict response to AADs.
y contrast, rs10033464 at 4q25 in regression analysis under
oth the dominant and additive models was significantly
ssociated with successful rhythm control in patients with
ypical AF carrying the ancestral allele (wild type) versus
arriers of variant allele (odds ratio [OR]: 4.59, 95%
onfidence interval [CI]: 1.82 to 11.5, p  0.0012 and OR:
3.03, 95% CI: 1.41 to 6.50, p  0.004, respectively). This
association persisted after correction for multiple clinical
factors (OR: 4.70, 95% CI: 1.83 to 12.0, p  0.0013 and
OR: 3.44, 95% CI: 1.52 to 7.76, p  0.003, respectively)
(Table 3).
There was a differential response to the class of AADs in
variants of rs10033464. Wild types responded better to class
III AADs, p  0.02, whereas carriers of variant allele
responded better to class I AADs, p  0.02 (Table 4).
In the validation cohort, 143 (72%) patients met the
criteria for rhythm control. Response to therapy was again
significantly associated with rs10033464; chi-square 
.042. In similar genetic regression models as the discovery
ort
t
Validation (n  198) p Value* p Value†
Typical 73 Lone 27 0.28 0.28
65 11 51 14 0.07 0.3
55 13 40 14 0.18 0.6
94 (65) 35 (66) 0.9 0.3
100 (50) 0 (0) 0.11 —
36 (18) 0 (0) 0.25 —
23 (12) 0 (0) 0.39 —
30 (15) 0 (0) 0.85 —
43 8 41 6.0 0.005 0.56
53 11 56 12 0.05 0.6y Coh
Cohor
)
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predictor of successful rhythm control in wild type: domi-
nant model OR: 1.496, 95% CI: 1.02 to 3.06, p  0.04. In
the additive model, we observed a similar trend as in the
discovery cohort; however, it did not reach statistical
significance: OR: 1.318, 95% CI: 0.62 to 2.79, p  0.46
(Table 3).
Response to AADs in the validation cohort followed
the same trend as the discovery cohort, with wild types
responding favorably to class III AADs (61% vs. 34%,
p  0.02) versus carriers of variant allele at rs10033464
responding favorably to class I AADs (39% vs. 67%, p 
0.01) (Table 4).
AF recurrence and genetic polymorphism. In 12-month
follow-up, 184 (39%) patients in the discovery cohort had
AF recurrence (n 478), of which 57 (12% of 478) patients
had AF captured by Holter or event monitor, and 10 (2% of
478) patients had AF captured by pacemaker interrogations.
In the validation cohort (n  198), 73 (38%) patients had
AF recurrence, of which 20 (10% of 198) patients had AF
captured by Holter or event monitor. AF recurrence among
carriers of the variant allele and wild type for each SNP in
each cohort is shown in Table 5.
In both cohorts under univariate analysis, only rs10033464
showed significance associated with AF recurrence. Carriers
of the variant allele at rs10033464 had greater AF recur-
rence compared with wild types; 46% versus 36%, p  0.06,
in the discovery cohort and 51% versus 32%, p  0.013, in
the validation cohort. In the multivariable dominant ad-
justed model, carriers of the variant allele at rs10033464 had
greater OR of AF recurrence: OR: 3.27, 95% CI: 1.77 to
6.04, p  0.001 in the discovery cohort and OR: 4.31, 95%
CI: 1.98 to 9.4, p  0.001 in the validation cohort (Table 6).
Discussion
This study demonstrates a pharmacogenomics interaction:
significant modulation of symptomatic AF burden and AF
Genotype Frequencies in the Study PopulationTable 2 Genotype Frequencies in the Study
SNP Response
Discovery cohort
rs2200733 (4q25) n  477 Responders (398
Nonresponders (7
rs10033464 (4q25) n  477 Responders (398
Nonresponders (7
rs7193343 (16q22) n  464 Responders (386
Nonresponders (7
rs13376333 (1q21) n  466 Responders (387
Nonresponders (7
Validation cohort
rs10033464 (4q25) n  198 Responders (143
Nonresponders (5
MAF  minor allele frequency; SNP  single nucleotide polymorphismrecurrence between a common SNP on chromosome 4q25 t(rs10033464) and response to AAD therapy in patients with
AF. It further provides evidence for an important role of
genetic polymorphisms, not only in the pathophysiology of
AF, but also in response to pharmacological therapy.
The potential mechanism of action of variants at the
chromosome 4q25 locus tagged by the 2 noncoding SNPs is
unknown, and may be mediated through effects of distant
genes. However, it is interesting that the closest gene,
located approximately 90 kb centromeric, is the paired-like
homeodomain transcription factor 2 (PITX2) with an iso-
form implicated in early cardiac development (22–24).
Mouse pitx2 knockouts have demonstrated a critical role for
1 isoform, pitx2c, in left–right asymmetry, specifically the
development of the left atrium (24). Loss of pitx2c leads to
right atrial isomerization and a failure to suppress a default
pathway for sinus node development of the pulmonary
myocardium, or the sleeve of cardiomyocytes extending
from the left atrium into the initial portion of the pulmo-
nary vein. Importantly, this area is now recognized as a
common source for the ectopic atrial activity necessary for
the initiation and propagation of AF (24,25). Recently,
novel AF susceptibility alleles in addition to rs2200733 and
rs10033464 have been identified on chromosome 4q25.
This provides evidence of multiple susceptibility signals at
chromosome 4q25 and may help localize regulatory ele-
ments at this locus with biological relevance in the patho-
genesis of AF (26).
Microarray analysis of pitx2 null-mutant and control
mice hearts revealed up-regulation of Kcnq1, a potassium
channel gene that has been associated with gain-of-function
mutations in familial AF (8,27). A recent study by Voigt et
al. (28) looked at unequal left-to-right distribution of
inward rectifier K currents in subjects with paroxysmal AF.
hey found a 2-fold greater basal current in left atria
ompared with right atria, and 2-fold greater protein ex-
ression of IK1 (Kir2.1) in paroxysmal and chronic AF.
hysiologically, a gain-of-function potassium channel mu-
lation
MAF Wild Type (%)
Variant Allele
Carriers (%)
16 70 30
15 71 29
11 79 21
16 68 32
20 63 37
21 63 37
38 39 61
35 41 59
16.7 67 33
12 71 29Popu
)
9)
)
9)
)
8)
)
9)
)
5)ation would be predicted to respond to higher doses of
Tables
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tice has a higher probability of patients experiencing dele-
terious side effects of these drugs and ultimate discontinu-
ation. In our cohorts, carriers of the rs10033464 variant
allele responded better to class I AADs: 41% versus 28% in
the discovery cohort and 67% versus 39% in the validation
cohort, p  0.05, suggesting that the 4q25 SNP likely
modulates other cardiac ion channels in addition to potas-
sium channels.
In a novel study, Kirchhof et al. (29), utilizing expression
arrays in Pitx2/ mice, identified alteration in a number of
cellular and molecular pathways in addition to potassium
channels, which might explain our findings. Although
studies in Pitx2-null mice have identified increased expres-
Logistic Regression Analysis of Genetic PredictTable 3 Logistic Regression Analysis of Gen
Unadjusted
SNP OR 95% CI
Discovery cohort
rs2200733 additive
All AF 0.91 0.57–1.45
Typical 0.98 0.42–2.33
Lone 0.67 0.36–1.27
rs2200733 dominant
All AF 0.99 0.58–1.68
Typical 0.89 0.31–2.53
Lone 0.75 0.37–1.50
rs10033464 additive
All AF 1.49 0.91–2.4
Typical 3.03† 1.41–6.50
Lone 1.07 0.50–2.26
rs10033464 dominant
All AF 1.73 1.02–2.95
Typical 4.59† 1.82–11.5
Lone 1.15 0.52–2.51
rs7193343 additive
All AF 1.07 0.69–1.66
Typical 1.14 0.49–2.67
Lone 0.90 0.52–1.57
rs7193343 dominant
All AF 0.99 0.60–1.65
Typical 0.80 0.29–2.16
Lone 0.99 0.50–1.94
rs13376333 additive
All AF 0.89 0.63–1.27
Typical 0.59 0.29–1.20
Lone 0.87 0.53–1.42
rs13376333 dominant
All AF 0.89 0.55–1.46
Typical 0.58 0.23–1.45
Validation cohort
rs10033464 additive
All AF 1.318 0.62–2.79
rs10033464 dominant
All AF 1.496† 1.02–3.06
*Adjusted for sex and AF subtype. †p  0.05.
CI  confidence interval; OR  odds ratio; other abbreviations as insion of potassium channel genes (kcna3, kcnk5), the func-tional consequences are unknown. Chinchilla et al. (30)
recently looked at the electrophysiological defects in atrial-
specific Pitx2-deficient mice. Their data show significantly
more depolarized resting membrane potential in Pitx2-
deficient mice (84 mV vs. 87 mV) as compared with
littermate control mice (p  0.05), suggesting decreased
expression and/or function of the channels that generate
ionic currents involved in the control of the resting mem-
brane potential, for instance, the inward rectifier current
(Ik1). By utilizing quantitative RT-PCR, they show severely
reduced expression of a number of potassium channels genes
such as Kcnj2, and a gain-of-function consequence for both
inward and outward Kir2.1 currents. In addition, atrial
deletion of Pitx2 lead to down-regulation of Scn5a and
f Response to AADsPredictors of Response to AADs
Adjusted*
p Value OR 95% CI p Value
0.69 0.91 0.57–1.45 0.68
0.97 0.94 0.39–2.29 0.89
0.22 0.66 0.35–1.27 0.21
0.95 0.98 0.57–1.67 0.93
0.83 0.82 0.28–2.37 0.71
0.41 0.75 0.36–1.53 0.42
0.11 1.48 0.91–2.42 0.11
0.004 3.44† 1.52–7.76 0.003
0.86 1.01 0.47–2.19 0.97
0.04 1.74 1.02–2.97 0.04
0.0012 4.70† 1.83–12.0 0.0013
0.73 1.1 0.49–2.45 0.82
0.75 1.08 0.69–1.66 0.75
0.77 1.11 0.46–2.67 0.80
0.71 0.92 0.52–1.61 0.76
0.98 0.99 0.62–1.65 0.98
0.65 0.75 0.27–2.06 0.58
0.96 1.1 0.52–2.00 0.97
0.51 0.9 0.63–1.28 0.55
0.14 0.6 0.29–2.23 0.16
0.57 0.9 0.55–1.49 0.68
0.64 0.91 0.55–1.49 0.70
0.25 0.61 0.24–1.53 0.29
0.46 1.317 0.72–2.79 0.47
0.04 1.498† 1.02–3.06 0.04
1 and 2.ors oeticScn1b, both of which have been associated with familial
544 Parvez et al. JACC Vol. 60, No. 6, 2012
Common AF Variants and Response to Antiarrhythmics August 7, 2012:539–45cases of AF. These recent data strongly support our finding
that response to AADs may also be modulated by the 4q25
SNPs, with the mechanism related to modulation of cardiac
ion channel expression in the heart. As there is likely to be
differential expression of ion channels in the human heart
compared with mice, it is not surprising that there was a
differential response to the class of AADs.
The ZFHX3 (zinc finger homeobox 3) gene on chromo-
some 16q22 encodes a transcription factor that was origi-
nally identified as a regulator of alpha-fetoprotein expres-
sion (31). ZFHX3 has been associated with Kawasaki
disease, as well as malignancies such as prostate cancer.
However, in human cardiac and pulmonary tissue, its
expression pattern and mechanism are not fully known (32).
Two separate genome-wide association studies established
an AF susceptibility locus on chromosome 16q22 near
ZFHX3 (14,15). More recently, a novel genetic locus on
chromosome 1q21 was identified for early-onset or lone AF.
The SNP (rs13376333) is located in the intronic region of
chromosome 1q21 between the first and second exons of the
calcium-activated potassium channel gene KCNN3 (16).
The precise mechanism by which it causes AF remains to be
determined.
It is also possible that common genetic variants identify
AF subtypes with differing drug responses. For example,
recognizing that activation of the renin-angiotensin system
is implicated in AF, 1 study examined the impact of the
common angiotensin-converting enzyme insertion/deletion
(ID) polymorphism on response to AAD therapy. An analysis of
Response (%) Distribution of AAD byClass Among Re ponders f r SNP rs10033464Table 4 Response (%) Distribution of AAD byClass Among Responders for SNP rs10033464
Drug Class Wild Type
Variant Allele
Carriers p Value
Discovery cohort, n 309 90
Class 1 87 (28%) 37 (41%) 0.02
Class III 222 (72%) 53 (59%) 0.02
Validation cohort, n 97 46
Class 1 37 (39%) 30 (67%) 0.01
Class III 60 (61%) 16 (34%) 0.02
Values are n (%).
AAD  antiarrhythmic drugs; SNP  single nucleotide polymorphism.
Distribution of AF Recurrence by GenotypeTable 5 Distribution of AF Recurrence by Genotype
SNP
Carriers of
Variant Allele Wild Type p Value*
Discovery cohort
rs2200733 60/139 (43%) 123/334 (37%) 0.19
rs10033464 50/108 (46%) 133/365 (36%) 0.06
rs7193343 67/173 (37%) 114/287 (40%) 0.83
rs13376333 113/279 (40%) 68/183 (37%) 0.47
Validation cohort
rs10033464 30/59 (51%) 43/134 (32%) 0.013
Numerator indicates total number of patients with AF recurrence, and denominator indicates total
number of patients by genotype. *Univariate analysis (chi-square).
Abbreviations as in Tables 1 and 2.213 subjects treated with rhythm control showed that lone
AF and double-deletion (DD)/ID genotypes were highly
significant predictors of failure of drug therapy (20). By
contrast, no relationship between common SNPs in the
beta1-adrenergic receptor (resulting in G389R and S49G)
and response to ventricular rate-control therapy in a group
of 279 patients managed with rate control was identified
(33). These findings indicate that variable mechanisms
contribute to AF susceptibility, and suggest therefore that
response to therapy may also be genotype dependent.
Study limitations. There are certain limitations to this
study that should be acknowledged. Although this was a
retrospective analysis, patients were enrolled prospectively,
and more important, response to AAD therapy was defined
a priori without knowledge of the genotypes. The recessive
logistic regression model was not performed due to the
limited number of homozygous carriers. The sample size for
the validation cohort was underpowered to detect allelic
effect in the additive genetic model. With a follow-up
period of 12 months and our criteria to document AF
recurrence by 12-lead ECG at 3, 6, and 12 months, or by
Holter monitoring or 30-day event recorder, and in some
patients, from pacemaker interrogations, we might not have
been able to capture asymptomatic AF in all patients. Both
study cohorts were similar with respect to baseline demo-
graphics, but patients with typical AF in the validation
cohort had well-preserved left ventricular ejection fraction
and small left atrial size. Finally, our study looked at both
reduction in symptomatic AF burden score as a reflection of
successful rhythm control and AF recurrence, with both
outcomes showing similar association with the same poly-
morphism at 4q25, but considering the retrospective nature
of our study, a larger prospective randomized study is
needed to fully appreciate this difference.
Conclusions
Our data support the hypothesis that a common SNP on
chromosome 4q25 associated with AF modulates response
to AAD therapy and points to a potential role for stratifi-
cation of therapeutic approaches by genotype. Our findings
may potentially impact the management of a large number
of patients with AF because 19% to 22% of different AF
Multivariable Logistic Regression Analysisfor Genetic Predictors of AF RecurrenceTable 6 Multiva iabl Logi tic Regression Analysisfor Genetic Predictors of AF Recurrence
SNP OR 95% CI p Value
Discovery cohort
rs2200733 1.26 0.70–2.14 0.40
rs10033464 3.27 1.77–6.04 0.001
rs7193343 0.80 0.40–1.33 0.40
rs13376333 1.10 0.60–1.80 0.70
Validation cohort
Rs10033464 4.31 1.98–9.40 0.001
Abbreviations as in Tables 3 and 5.populations carry this variant (17). However, this hypothesis
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August 7, 2012:539–45 Common AF Variants and Response to Antiarrhythmicscan only be truly evaluated in the context of a clinical trial,
and these findings should be confirmed in randomized
studies before tailoring AAD therapy for AF based on 4q25
genotype. The high recurrence of AF (30% to 50%) on
AADs, added to the risk, albeit small, of life-threatening
proarrhythmia, strongly supports the need for randomized
pharmacogenetic trials and suggests that genetic assessment
of therapeutic efficacy should be incorporated into all future
trials of therapy for AF. If the current findings are con-
firmed, tailoring therapy on the basis of the 4q25 genotype
is not only feasible, but may reduce the cost burden
associated with this arrhythmia.
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